Lundbeckfonden Emerge
Lundbeckfonden Emerge seeks to identify and initiate commercial development of scientific opportunities which it considers from its analysis have high commercial potential. The main objective is to turn scientific discoveries and early stage opportunities into commercial ventures with a maturity that allows for full venture financing.
Lundbeckfonden Emerge not only offers limited financing for selected cases but also offers seasoned advice or direct participation in new ventures, as part of its unique model to optimize the outcome of the venture to the benefit of all stakeholders. Lundbeckfonden Emerge will seek to develop select projects together with founders and will take on an active role from mentoring to active project management, as is considered optimal for the outcome of the specific project. In this way, Lundbeckfonden Emerge is not a replication of traditional seed funds, but rather a unique way of using research funds to get to commercially viable projects.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
9 past transactions
NMD Pharma
Series B in 2023
NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.
NMD Pharma
Venture Round in 2022
NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.
Cytoki Pharma
Series A in 2021
Cytoki Pharma ApS is a biotechnology company based in Værløse, Denmark, founded in 2019. The company is focused on developing innovative treatments for diseases with significant unmet medical needs, particularly those related to epithelial injuries. As a pre-clinical entity, Cytoki Pharma's lead program centers on an engineered long-acting IL-22 protein, which has been licensed from a major pharmaceutical company. IL-22 plays a crucial role in the immune response, acting as a signal for tissue survival and repair following injury. By harnessing the therapeutic potential of this cytokine, Cytoki Pharma aims to create effective solutions for organ injuries and improve patient outcomes in conditions that currently lack adequate treatment options.
IO Biotech
Series B in 2021
IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its unique T-win technology platform, the company creates first-in-class immune-modulating cancer vaccines that aim to activate T cells specific to immune-suppressive molecules. This approach allows for the simultaneous targeting and disruption of multiple pathways that tumors exploit to evade the immune response. IO Biotech has demonstrated a strong capability in advancing its preclinical and clinical candidates, with its two leading compounds targeting IDO and PD-L1 currently in clinical development, while several others are in the preclinical phase.
AFYX Therapeutics
Debt Financing in 2019
AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, focused on developing and manufacturing treatments for mucosal diseases. Established in 2014, the company is known for its flagship product, the Rivelin® patch, which is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver medication directly to the affected area. By offering targeted therapies for conditions that currently lack approved treatment options, AFYX Therapeutics aims to enhance patient relief and support recovery without disrupting daily activities.
NMD Pharma
Series A in 2018
NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.
SNIPR Biome
Seed Round in 2017
SNIPR Biome is a biotechnology company developing CRISPR-based therapies for treating microbial diseases. Founded in 2017 and headquartered in Copenhagen, Denmark, the company leverages CRISPR technology to selectively eliminate harmful bacteria by targeting their specific DNA sequences.
AFYX Therapeutics
Series A in 2017
AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, focused on developing and manufacturing treatments for mucosal diseases. Established in 2014, the company is known for its flagship product, the Rivelin® patch, which is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver medication directly to the affected area. By offering targeted therapies for conditions that currently lack approved treatment options, AFYX Therapeutics aims to enhance patient relief and support recovery without disrupting daily activities.
NMD Pharma
Venture Round in 2016
NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.